Jonathan Allan sold $445k of STOK
GENERAL COUNSEL & CORP SEC at Stoke Therapeutics, Inc.. 22,117 shares at an average of $20.11, traded Aug 29, 2025, filed Sep 3, 2025.
Score components
- +15RoleOfficer
- +17Trade size$445k at market
- +20Share of holdings soldSold 89% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-023589, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 29, 2025 | MOption exercise Common Stock10b5-1 | +850 | $7.07 | $6,010 | 24,798 | Sep 3, 2025 |
| Aug 29, 2025 | SOpen-market sale Common Stock10b5-1 | -850 | $20.00 | $17k | 23,948 | Sep 3, 2025 |
| Sep 2, 2025 | MOption exercise Common Stock10b5-1 | +9,150 | $7.07 | $65k | 33,098 | Sep 3, 2025 |
| Sep 2, 2025 | SOpen-market sale Common Stock10b5-1 | -14,922 | $20.14 | $300k | 18,176 | Sep 3, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -6,345 | $20.07 | $127k | 11,831 | Sep 3, 2025 |
| Aug 29, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -850 | $0.00 | $0 | 24,951 | Sep 3, 2025 |
| Sep 2, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,150 | $0.00 | $0 | 15,801 | Sep 3, 2025 |
Related signals
Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $17k 627 shares | -3% | |
| 8Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $27k 1,051 shares | -5% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $170k 5,545 shares | -22% | |
| 38Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $1.2M 61,885 shares | -40% | |
| 28Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $31k 1,683 shares | -7% | |
| 35Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $221k 12,126 shares | -7% | |
| 25Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $206k 13,712 shares | -41% | |
| 55Moderate | Stoke Therapeutics, Inc. | Skorpios Trust owner | $31M 3,000,000 shares | -43% | |
| 17Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $82k 8,216 shares | -24% | |
| 18Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $267k 26,631 shares | -44% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.